Kim JW, Chung JY, Ylaya K, et al. - Researchers sought to determine whether cancer stem cell markers expression have clinical significance in the context of small intestinal adenocarcinoma with the KRAS genotype. They evaluated SOX2, NANOG, and OCT4 expression, and further assessed their potential link with KRAS in 185 Korean patients suffering from small intestinal adenocarcinomas, which were obtained from 22 institutions in South Korea. A total of 65 (35.1%), 94 (50.8%), and 82 (44.3%) of patients were found to have positive expression of SOX2, NANOG, and OCT4, respectively. Worse overall survival in patients with high SOX2 (SOX2+) expression was found vs those with low SOX2 (SOX2−) expression. Significantly shorter overall survival was experienced by patients with SOX2+/mutant KRAS (KRAS ^MT ) vs those with SOX2−/KRAS ^WT . Multivariate analysis revealed the following independent prognostic factors for worse overall survival: SOX2+, distal location, high pT and pN categories, microsatellite stable, and absence of predisposing diseases. Findings indicate the potential of SOX2 expression to serve as a predictor of clinical results in cases with small intestinal adenocarcinomas.